1. Home
  2. AVT vs ERAS Comparison

AVT vs ERAS Comparison

Compare AVT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avnet Inc.

AVT

Avnet Inc.

HOLD

Current Price

$80.80

Market Cap

6.4B

Sector

Technology

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$11.17

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVT
ERAS
Founded
1921
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.5B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
AVT
ERAS
Price
$80.80
$11.17
Analyst Decision
Hold
Strong Buy
Analyst Count
3
12
Target Price
$59.33
$14.25
AVG Volume (30 Days)
1.2M
9.1M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
1.72%
N/A
EPS Growth
N/A
36.23
EPS
1.36
N/A
Revenue
$22,200,754,000.00
N/A
Revenue This Year
$14.39
N/A
Revenue Next Year
$5.44
N/A
P/E Ratio
$60.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.25
$1.06
52 Week High
$84.07
$24.28

Technical Indicators

Market Signals
Indicator
AVT
ERAS
Relative Strength Index (RSI) 74.42 35.19
Support Level $58.49 $2.07
Resistance Level N/A $17.17
Average True Range (ATR) 2.32 1.90
MACD 0.62 -1.33
Stochastic Oscillator 78.43 14.12

Price Performance

Historical Comparison
AVT
ERAS

About AVT Avnet Inc.

Avnet Inc is an electronic component technology distributor and solutions provider. It serves customers from startups and mid-sized businesses to enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). The group operates in the Electronic Components segment and supports high and medium-volume customers to markets, sells, and distributes electronic components, and the Farnell segment supports lower-volume customers that need electronic components quickly to develop, prototype, and test their products. Its geographic regions are the Americas, EMEA, and Asia.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: